Rehovot biotech firm to collaborate with a US Department of Veterans Affairs Institution

Rehovot based Dermipsor Ltd. said it signed a cooperative research and development agreement with the Department of Veterans Affairs Boston Research Institute Inc. The collaboration's framework under the agreement covers the advancement of Phase II and III trials. The agreement initially will focus on implementing a scalp psoriasis Phase II study with Dermipsor's DPS-102, a nonsteroidal synergistic combination topical treatment, which is scheduled to begin in the fourth quarter. The company said it also is continuing preparations for its plaque psoriasis Phase III trial with its leading drug DPS-101.

tmcnet.com